16 recruiting, 15 completed, 6 terminated, 5 active not recruiting. 17 Phase 2, 16 Phase 1, 13 Not applicable, 1 Phase 3.
Follow Metastatic Lung Cancer: new trials by email Literature Review of Metastatic Lung Cancer trials Research Report on Metastatic Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | University of Chicago | 39 | 2026-12-12 | 2026-06-16 |
| Vapor Ablation for Localized Cancer Lesions Bronchoscopic Thermal Vapor Ablation - Non Small Cell Lung Cancer, Metastatic Lung Cancer | Not applicable | Not yet recruiting | Uptake Medical Technology, Inc. | 10 | 2026-09-01 | 2025-02-27 |
| Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer Pulse radiotherapy - Non Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 1 | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 32 | 2026-08-20 | 2026-08-24 |
| Effects of Infusion Timing on Treatment Response in Solid Tumors PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-1 inhibitor monotherapy - 2 cycles before 12:00PM - Lung Cancer, Non-small Cell Lung Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 238 | 2026-08-03 | 2026-09-15 |
| A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer ANS014004 + PLB1004, ANS014004 + Osimertinib - Non-Small Cell Lung Cancer, EGFR Mutation | Phase 1 / Phase 2 | Not yet recruiting | Beijing Pearl Biotechnology Limited Liability Company | 253 | 2026-06-01 | 2025-12-16 |
| Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study) Hospital Anxiety and Depression scale (HAD), Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13), Questionnaire Aix-Marseille-Université (AMU) - Metastatic Lung Cancer, Metastatic NSCLC | Recruiting | GFPC Investigation | 1000 | 2025-07-02 | 2026-04-27 | |
| Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway Assessments of neuropsychiatric, neurocognitive and psychosocial alterations - Metastatic Lung Cancer, Metastatic Lung Cancer With ALK/ROS1 Fusion | Recruiting | Hospices Civils de Lyon | 20 | 2025-01-16 | 2025-12-30 | |
| Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients Blood Sampling (2*8mL Tubes), PBMC Sampling (1*8mL Tubes), Paxgene Sampling - Lung Cancer, Carcinoma, Non-Small-Cell Lung | Not applicable | Recruiting | Nantes University Hospital | 730 | 2024-12-10 | 2026-10-05 |
| Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors BBO-10203, Trastuzumab, Fulvestrant - Solid Tumor, Adult, Metastatic Breast Cancer | Phase 1 | Recruiting | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 392 | 2024-10-29 | 2026-10-01 |
| Exercise as Maintenance Therapy in Advanced Lung Cancer Exercise Intervention - Lung Cancer, Non Small Cell Lung Cancer | Not applicable | Terminated | Indiana University | 2 | 2024-10-15 | 2026-04-27 |
| Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer BBO-8520, Pembrolizumab, BBO-10203 - Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | Phase 1 | Recruiting | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 350 | 2024-05-22 | 2026-09-03 |
| INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 Tusamitamab ravtansine - Metastatic Lung Cancer, Metastatic Breast Cancer | Phase 2 | Withdrawn | Erasmus Medical Center | 2024-02-16 | 2024-02-28 | |
| Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients Single drug chemotherapy plus immunotherapy - Elderly Patients, Metastatic Lung Cancer | Phase 2 | Recruiting | Hubei Cancer Hospital | 49 | 2024-02-01 | 2024-03-15 |
| Definitive Radiation for High-Risk Spine Metastases SBRT to the spine - Metastatic Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | Stony Brook University | 26 | 2023-12-14 | 2025-05-14 |
| CALM: Managing Distress in Malignant Brain Cancer CALM, Treatment as usual - Brain Tumor, Brain Metastases | Not applicable | Completed | Virginia Commonwealth University | 60 | 2023-11-10 | 2025-10-08 |
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors OBX-115 - Tumor Skin, Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Obsidian Therapeutics, Inc. | 254 | 2023-10-25 | 2026-10-05 |
| A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer FoundationOne® Liquid CDx Assay, Standard of Care Diagnostic Pathway - Metastatic Lung Cancer, Metastatic Gastrointestinal Cancer | Not applicable | Completed | Hoffmann-La Roche | 463 | 2023-09-14 | 2025-12-17 |
| Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer Antibiotics, FMT (Fecal Microbiota Transplantation) - Metastatic Lung Cancer | Phase 2 | Recruiting | Soroka University Medical Center | 80 | 2023-09-01 | 2023-10-02 |
| Emulation of the KEYNOTE-189 Trial Using Electronic Health Records Pembrolizumab + Pemetrexed-Platinum, Pemetrexed-Platinum - Non-small Cell Lung Cancer, Metastatic Lung Cancer | Completed | Aetion, Inc. | 1854 | 2023-06-05 | 2023-09-13 | |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1 / Phase 2 | Recruiting | Institut de Recherches Internationales Servier | 554 | 2023-04-18 | 2026-10-13 |
Showing 20 of 49. Sign in to see all of them.
Lung Neoplasms (49) · Carcinoma, Non-Small-Cell Lung (25) · Breast Neoplasms (12) · Neoplasm Metastasis (9) · Colorectal Neoplasms (5) · Melanoma (5) · Neoplasms (5) · Brain Neoplasms (4) · Colonic Neoplasms (4) · Pancreatic Neoplasms (4) · Prostatic Neoplasms (4) · Stomach Neoplasms (4) · Small Cell Lung Carcinoma (3) · Carcinoma, Hepatocellular (2) · Head and Neck Neoplasms (2)
Lung Diseases (48) · Neoplasms by Site (48) · Respiratory Tract Diseases (48) · Respiratory Tract Neoplasms (48) · Thoracic Neoplasms (48) · Neoplasms (44) · Bronchial Neoplasms (24) · Carcinoma, Bronchogenic (24) · Skin Diseases (14) · Skin and Connective Tissue Diseases (14) · Digestive System Diseases (13) · Digestive System Neoplasms (13) · Breast Diseases (12) · Gastrointestinal Diseases (12) · Gastrointestinal Neoplasms (11)
Carboplatin (4) · pembrolizumab (4) · Gemcitabine (3) · Nivolumab (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · Blood Specimen Collection (2) · Pemetrexed (2) · Radiosurgery (2) · Trastuzumab (2) · durvalumab (2) · 4-amino-4'-hydroxylaminodiphenylsulfone (1) · Anti-Bacterial Agents (1) · Bevacizumab (1) · Cetuximab (1)
AIO-Studien-gGmbH (2) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (2) · Uptake Medical Technology, Inc. (2) · Aetion, Inc. (1) · Asana BioSciences (1) · Beijing Pearl Biotechnology Limited Liability Company (1) · Black Diamond Therapeutics, Inc. (1) · Blueprint Medicines Corporation (1) · Boston Scientific Corporation (1) · Centre Leon Berard (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Clovis Oncology, Inc. (1) · Cota Inc. (1) · Erasmus Medical Center (1) · GFPC Investigation (1)
United States (26) · France (15) · Spain (7) · Australia (5) · Canada (5) · Germany (5) · Italy (5) · China (2) · Denmark (2) · Israel (2) · Japan (2) · Netherlands (2) · South Korea (2) · Taiwan (2) · Austria (1)
Ashlee Loughan, Ph.D (1) · Daniel Keizman, MD (1) · Daniel Steinfort, MD, PhD (1) · David Merola, PharmD, PhD (1) · Debbie Robbrecht, Dr. (1) · Deena Atieh Graham, MD (1) · Eric Wachter, PhD (1) · Farastuk Bozorgmehr, Dr. (1) · Guang Han (1) · Heike Peulen, MD (1)
PMID 26243393, PMID 27455330, PMID 29122363, PMID 31703637, PMID 32321565, PMID 33541288, PMID 35844029, PMID 39694415, PMID 40702361
2015 (1), 2016 (1), 2023 (1), 2025 (1), P30CA012197 (1), R03CA235171 (1), R21CA259964 (1)